A disease model resource reveals core principles of tissue-specific cancer evolution

Area of Science:

• Oncology
• Genomics
• Cancer Biology

Background:

• Oncogenes like KRAS show significant tissue-specific effects in cancer initiation and progression.
• The molecular determinants driving this tissue specificity remain largely unknown.
• Understanding these differences is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To investigate the core principles underlying the tissue-specific evolution of KRAS-initiated cancers.
• To identify the genetic and cellular factors that dictate KRAS oncogenic potential across different tissues.
• To establish a comprehensive resource for studying KRAS-driven cancers.

Main Methods:

• Development and utilization of the Mouse Cancer Cell line Atlas (MCCA), a resource of 590 characterized models.
• Comparative and functional studies integrating MCCA data with human cohorts and mouse models.
• Analysis of mutant KRAS dosage, collaborating alterations, and tumor suppressor interactions.

Main Results:

• Mutant KRAS dosage gain has cell-type-specific effects, influencing cancer initiation timing (e.g., pancreatic cancer).
• Tissue- and stage-specific requirements (e.g., blocking differentiation in the intestine) select for KRAS-collaborating alterations.
• Context-dependent interactions between KRAS and tumor suppressors, along with reciprocal dosage sensitivities, dictate entity-specific cancer gene alteration patterns.

Conclusions:

• Intrinsic and acquired factors instruct cancer evolution differently across tissues, leading to predictable molecular and phenotypic outcomes.
• The study advances mechanistic understanding of cancer genomes and the tissue-specific nature of oncogenic drivers.
• The MCCA resource provides a platform for future research into cancer heterogeneity and targeted therapeutic strategies.